Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A
The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1α (SDF-1α); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1α. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1α or a polynucleotide codes a protein thereof.
1. A method for treating a peripheral artery disease, the method comprising a step of local, intramuscular administration of a composition to a subject in need thereof, the composition comprising, a plasmid comprising a sequence encoding both full-length hepatocyte growth factor (flHGF) comprising the amino acid sequence of SEQ ID NO: 2 and deleted variant hepatocyte growth factor (dHGF) comprising the amino acid sequence of SEQ ID NO: 3, operably linked to a promoter, and a plasmid comprising a sequence encoding stromal cell derived factor 1α (SDF-1α) comprising the amino acid sequence of SEQ ID NO: 8, operably linked to a promoter, thereby treating a peripheral artery disease.
2. The method of claim 1 , wherein the sequence encoding both the flHGF and the dHGF comprises the nucleotide sequence of SEQ ID NO: 5.
3. The method of claim 1 , wherein the sequence encoding both the flHGF and the dHGF comprises the nucleotide sequence of SEQ ID NO: 7.
4. The method of claim 1 , wherein the sequence encoding SDF-1α comprises the nucleotide sequence of SEQ ID NO: 6.
5. The method of claim 1 , wherein the peripheral artery disease is ischemic limb disease.
6. The method of claim 1 , wherein the plasmid is pCK.
7. The method of claim 1 , wherein the subject is selected from the group consisting of human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon, and rhesus monkey.
8. The method of claim 7 , wherein the subject is human.
9. The method of claim 1 , wherein the plasmids are administered at a dose of 1 μg to 100 mg for each.